Viyash Scientific Limited

rs,

ww.viyash.com CIN: L99999TS1985PLC196357 May 19, 2026 To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza, B

₹9,200 Million

Scientific : Q4 FY26 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA Margin ₹9,200 Million +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x

19.1%

Y26 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA Margin ₹9,200 Million +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Deb

₹2,001 Million

ce Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA Margin ₹9,200 Million +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in F

63.8 %

values in ₹ Mn Revenues EBITDA¹ EBITDA Margin ₹9,200 Million +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net D

21.7%

Mn Revenues EBITDA¹ EBITDA Margin ₹9,200 Million +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,51

590 bps

nues EBITDA¹ EBITDA Margin ₹9,200 Million +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,511 Notes:

0.2x

llion +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,511 Notes: 1. EBITDA are adjusted for ESOP costs

₹ 1661

YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,511 Notes: 1. EBITDA are adjusted for ESOP costs 4 Viyash : FY26

1.0x

Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,511 Notes: 1. EBITDA are adjusted for ESOP costs 4 Viyash : FY26 Performa

₹ 4,511

21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,511 Notes: 1. EBITDA are adjusted for ESOP costs 4 Viyash : FY26 Performance Highlights All values in

₹34,203 Million

ts 4 Viyash : FY26 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA¹ Margin ₹34,203 Million +13.8% YoY ₹7,025 Million +59.6 % YoY 20.5% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x

“As we enter FY27, we are excited about our product pipeline and growth roadmap.”

“EBITDA are adjusted for ESOP costs 3 Viyash Scientific : Q4 FY26 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA Margin ₹9,200 Million +19.1% YoY ₹2,001 Million +63.8 % YoY 21.7% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,511 Notes: 1.”

“EBITDA are adjusted for ESOP costs 4 Viyash : FY26 Performance Highlights All values in ₹ Mn Revenues EBITDA¹ EBITDA¹ Margin ₹34,203 Million +13.8% YoY ₹7,025 Million +59.6 % YoY 20.5% +590 bps YoY Net Debt to LTM EBITDA¹ 0.2x Net Debt- ₹ 1661 Mn 1.0x in FY25 Net Debt - ₹ 4,511 Notes: 1.”

“8 Business Update Key Highlights from Q4 FY26 Facility Inspections 2 Regulatory Audits 36 Customer audits Regulatory Approvals Launches 4APIs: (USDMF-1 ; EDQM-1; JDMF-1, ANVISA-1) 4 FDFs- USFDA 5 APIs (2-USA, 2- MENA, 1- CA) 1 FDF (USA) Products Filed Validations Completed R&D Pipeline 4 APIs – USDMF (2), JDMF (1).”

“CA DMF (1) 3FDFs (USA) 6 APIs 1 FDF 19 Products 10 FY26: Further strengthened formulation business o Europe o Renewed EUGMP certification for Spanish manufacturing plant o Good business performance, led by Exports & Companion Animal Segment o Partnered with VetViva Richter for Canine Heart therapy o Initiated direct companion animal sales activities in Italy.”

Registered Office

1

Registered Office

3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 May 19, 2026 To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip code: 512529 Scrip code: VIYASH Dear Sir/ Madam, Subject: Investor Presentation for FY 2025-26 Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. This is for your information and appropriate dissemination. Thanking you, Yours faithfully, For Viyash Scientific Limited (